BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chapiro J, Duran R, Lin M, Schernthaner R, Lesage D, Wang Z, Savic LJ, Geschwind JF. Early survival prediction after intra-arterial therapies: a 3D quantitative MRI assessment of tumour response after TACE or radioembolization of colorectal cancer metastases to the liver. Eur Radiol 2015;25:1993-2003. [PMID: 25636420 DOI: 10.1007/s00330-015-3595-5] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 5.7] [Reference Citation Analysis]
Number Citing Articles
1 Fleckenstein FN, Schernthaner RE, Duran R, Sohn JH, Sahu S, Zhao Y, Hamm B, Gebauer B, Lin M, Geschwind JF, Chapiro J. 3D Quantitative tumour burden analysis in patients with hepatocellular carcinoma before TACE: comparing single-lesion vs. multi-lesion imaging biomarkers as predictors of patient survival. Eur Radiol 2016;26:3243-52. [PMID: 26762942 DOI: 10.1007/s00330-015-4168-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
2 Choi SJ, Kim J, Seo J, Kim HS, Lee JM, Park H. Parametric response mapping of dynamic CT for predicting intrahepatic recurrence of hepatocellular carcinoma after conventional transcatheter arterial chemoembolization. Eur Radiol 2016;26:225-34. [PMID: 25991485 DOI: 10.1007/s00330-015-3825-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
3 Marquez HP, Puippe G, Mathew RP, Alkadhi H, Pfammatter T, Fischer MA. CT Perfusion for Early Response Evaluation of Radiofrequency Ablation of Focal Liver Lesions: First Experience. Cardiovasc Intervent Radiol 2017;40:90-8. [PMID: 27812781 DOI: 10.1007/s00270-016-1444-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
4 Letzen BS, Malpani R, Miszczuk M, de Ruiter QMB, Petty CW, Rexha I, Nezami N, Laage-Gaupp F, Lin M, Schlachter TR, Chapiro J. Lipiodol as an intra-procedural imaging biomarker for liver tumor response to transarterial chemoembolization: Post-hoc analysis of a prospective clinical trial. Clin Imaging 2021;78:194-200. [PMID: 34022765 DOI: 10.1016/j.clinimag.2021.05.007] [Reference Citation Analysis]
5 Patella F, Pesapane F, Fumarola E, Zannoni S, Brambillasca P, Emili I, Costa G, Anderson V, Levy EB, Carrafiello G, Wood BJ. Assessment of the response of hepatocellular carcinoma to interventional radiology treatments. Future Oncol 2019;15:1791-804. [PMID: 31044615 DOI: 10.2217/fon-2018-0747] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
6 Smolka S, Chapiro J, Manzano W, Treilhard J, Reiner E, Deng Y, Zhao Y, Hamm B, Duncan JS, Gebauer B, Lin M, Geschwind JF. The impact of antiangiogenic therapy combined with Transarterial Chemoembolization on enhancement based quantitative tumor response assessment in patients with hepatocellular carcinoma. Clin Imaging 2017;46:1-7. [PMID: 28668723 DOI: 10.1016/j.clinimag.2017.05.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
7 Rexha I, Laage-Gaupp F, Chapiro J, Miszczuk MA, van Breugel JMM, Lin M, Konstantinidis M, Duran R, Gebauer B, Georgiades C, Hong K, Nezami N. Role of 3D quantitative tumor analysis for predicting overall survival after conventional chemoembolization of intrahepatic cholangiocarcinoma. Sci Rep 2021;11:9337. [PMID: 33927226 DOI: 10.1038/s41598-021-88426-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Koay EJ, Odisio BC, Javle M, Vauthey JN, Crane CH. Management of unresectable intrahepatic cholangiocarcinoma: how do we decide among the various liver-directed treatments? Hepatobiliary Surg Nutr 2017;6:105-16. [PMID: 28503558 DOI: 10.21037/hbsn.2017.01.16] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
9 Auer TA, Della Seta M, Collettini F, Chapiro J, Zschaeck S, Ghadjar P, Badakhshi H, Florange J, Hamm B, Budach V, Kaul D. Quantitative volumetric assessment of baseline enhancing tumor volume as an imaging biomarker predicts overall survival in patients with glioblastoma. Acta Radiol 2021;62:1200-7. [PMID: 32938221 DOI: 10.1177/0284185120953796] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Cheng CS, Chen L, Xie J, Chen Z. Multimodality palliative treatment with transarterial chemoembolization and high-intensity focused ultrasound for gastric leiomyosarcoma multiple liver metastasis pain: A case report. Medicine (Baltimore) 2019;98:e17328. [PMID: 31574868 DOI: 10.1097/MD.0000000000017328] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
11 Joo I, Kim HC, Kim GM, Paeng JC. Imaging Evaluation Following 90Y Radioembolization of Liver Tumors: What Radiologists Should Know. Korean J Radiol 2018;19:209-22. [PMID: 29520178 DOI: 10.3348/kjr.2018.19.2.209] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
12 Borde T, Nezami N, Gaupp FL, Savic LJ, Taddei T, Jaffe A, Strazzabosco M, Lin M, Duran R, Georgiades C, Hong K, Chapiro J. Optimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI. Radiology 2022;:212426. [PMID: 35412368 DOI: 10.1148/radiol.212426] [Reference Citation Analysis]
13 Akinwande O, Philips P, Scoggins CR, Kelly L, Tatum C, Hahl M, McMasters KM, Martin RC. Comparison of tumor response assessment methods in patients with metastatic colorectal cancer after locoregional therapy. J Surg Oncol 2016;113:443-8. [PMID: 27060707 DOI: 10.1002/jso.24141] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
14 Wu X, Chapiro J, Malhotra A. Cost-Effectiveness of Imaging Tumor Response Criteria in Hepatocellular Cancer After Transarterial Chemoembolization. J Am Coll Radiol 2021;18:927-34. [PMID: 33484726 DOI: 10.1016/j.jacr.2020.12.019] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Li B, Xu A, Huang Y, Peng L, Xiang K, Li Q, Tang D, You H, Tan F, Wang N. Oxygen-Challenge Blood Oxygen Level-Dependent Magnetic Resonance Imaging for Evaluation of Early Change of Hepatocellular Carcinoma to Chemoembolization: A Feasibility Study. Acad Radiol 2020:S1076-6332(20)30371-8. [PMID: 32747180 DOI: 10.1016/j.acra.2020.06.021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Vogl TJ, Schaefer P, Lehnert T, Nour-Eldin NE, Ackermann H, Mbalisike E, Hammerstingl R, Eichler K, Zangos S, Naguib NN. Intraprocedural blood volume measurement using C-arm CT as a predictor for treatment response of malignant liver tumours undergoing repetitive transarterial chemoembolization (TACE). Eur Radiol. 2016;26:755-763. [PMID: 26123407 DOI: 10.1007/s00330-015-3869-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
17 Sadick M, Richers J, Tuschy B, Schad LR, Schoenberg SO, Zöllner FG. Feasibility of quantitative MR-perfusion imaging to monitor treatment response after uterine artery embolization (UAE) in symptomatic uterus fibroids. Magn Reson Imaging 2019;59:31-8. [PMID: 30807812 DOI: 10.1016/j.mri.2019.02.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
18 Ram R, Kampalath R, Shenoy-Bhangle AS, Arora S, Kielar AZ, Mendiratta-Lala M. LI-RADS treatment response lexicon: review, refresh and resolve with emerging data. Abdom Radiol (NY) 2021;46:3549-57. [PMID: 34106301 DOI: 10.1007/s00261-021-03149-x] [Reference Citation Analysis]
19 Stroehl YW, Letzen BS, van Breugel JM, Geschwind JF, Chapiro J. Intra-arterial therapies for liver cancer: assessing tumor response. Expert Rev Anticancer Ther 2017;17:119-27. [PMID: 27983883 DOI: 10.1080/14737140.2017.1273775] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
20 Sahu S, Schernthaner R, Ardon R, Chapiro J, Zhao Y, Sohn JH, Fleckenstein F, Lin M, Geschwind JF, Duran R. Imaging Biomarkers of Tumor Response in Neuroendocrine Liver Metastases Treated with Transarterial Chemoembolization: Can Enhancing Tumor Burden of the Whole Liver Help Predict Patient Survival? Radiology. 2017;283:883-894. [PMID: 27831830 DOI: 10.1148/radiol.2016160838] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
21 Padia SA, Lewandowski RJ, Johnson GE, Sze DY, Ward TJ, Gaba RC, Baerlocher MO, Gates VL, Riaz A, Brown DB, Siddiqi NH, Walker TG, Silberzweig JE, Mitchell JW, Nikolic B, Salem R. Radioembolization of Hepatic Malignancies: Background, Quality Improvement Guidelines, and Future Directions. Journal of Vascular and Interventional Radiology 2017;28:1-15. [DOI: 10.1016/j.jvir.2016.09.024] [Cited by in Crossref: 54] [Cited by in F6Publishing: 45] [Article Influence: 10.8] [Reference Citation Analysis]
22 Dendy MS, Ludwig JM, Kim HS. Predictors and prognosticators for survival with Yttrium-90 radioembolization therapy for unresectable colorectal cancer liver metastasis. Oncotarget 2017;8:37912-22. [PMID: 28415671 DOI: 10.18632/oncotarget.16007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
23 Abbott EM, Falzone N, Lee BQ, Kartsonaki C, Winter H, Greenhalgh TA, McGowan DR, Syed N, Denis-Bacelar AM, Boardman P, Sharma RA, Vallis KA. The Impact of Radiobiologically Informed Dose Prescription on the Clinical Benefit of 90Y SIRT in Colorectal Cancer Patients. J Nucl Med 2020;61:1658-64. [PMID: 32358093 DOI: 10.2967/jnumed.119.233650] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
24 Tegel BR, Huber S, Savic LJ, Lin M, Gebauer B, Pollak J, Chapiro J. Quantification of contrast-uptake as imaging biomarker for disease progression of renal cell carcinoma after tumor ablation. Acta Radiol 2020;61:1708-16. [PMID: 32216452 DOI: 10.1177/0284185120909964] [Reference Citation Analysis]
25 Jakobs TF, Paprottka KJ, Raeßler F, Strobl F, Lehner S, Ilhan H, Trumm CG, Fendler WP, Sommer W, Paprottka PM. Robust evidence for long-term survival with 90Y radioembolization in chemorefractory liver-predominant metastatic colorectal cancer. Eur Radiol 2017;27:113-9. [PMID: 27059858 DOI: 10.1007/s00330-016-4345-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
26 Chen BB, Lin ZZ, Shao YY, Hsu C, Hsu CH, Cheng AL, Liang PC, Shih TT. Early Changes in DCE-MRI Biomarkers May Predict Survival Outcomes in Patients with Advanced Hepatocellular Carcinoma after Sorafenib Failure: Two Prospective Phase II Trials. Cancers (Basel) 2021;13:4962. [PMID: 34638446 DOI: 10.3390/cancers13194962] [Reference Citation Analysis]
27 Luedemann WM, Geisel D, Gebauer B, Schnapauff D, Chapiro J, Wieners G, Steffen I, Kahn J. Comparing HCC arterial tumour vascularisation on baseline imaging and after lipiodol cTACE: how do estimations of enhancing tumour volumes differ on contrast-enhanced MR and CT? Eur Radiol 2020;30:1601-8. [PMID: 31811428 DOI: 10.1007/s00330-019-06430-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
28 Lüdemann W, Kahn J, Pustelnik D, Hardt J, Böning G, Jonczyk M, Amthauer H, Gebauer B, Hamm B, Wieners G. Yttrium-90 radioembolization for unresectable hepatocellular carcinoma: predictive modeling strategies to anticipate tumor response and improve patient selection. Eur Radiol 2022. [PMID: 35230518 DOI: 10.1007/s00330-022-08585-x] [Reference Citation Analysis]
29 Ghosn M, Derbel H, Kharrat R, Oubaya N, Mulé S, Chalaye J, Regnault H, Amaddeo G, Itti E, Luciani A, Kobeiter H, Tacher V. Prediction of overall survival in patients with hepatocellular carcinoma treated with Y-90 radioembolization by imaging response criteria. Diagn Interv Imaging 2021;102:35-44. [PMID: 33012693 DOI: 10.1016/j.diii.2020.09.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
30 Miszczuk MA, Chapiro J, Geschwind JH, Thakur V, Nezami N, Laage-Gaupp F, Kulon M, van Breugel JMM, Fereydooni A, Lin M, Savic LJ, Tegel B, Wahlin T, Funai E, Schlachter T. Lipiodol as an Imaging Biomarker of Tumor Response After Conventional Transarterial Chemoembolization: Prospective Clinical Validation in Patients with Primary and Secondary Liver Cancer. Transl Oncol 2020;13:100742. [PMID: 32092672 DOI: 10.1016/j.tranon.2020.01.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
31 Chockalingam A, Duran R, Sohn JH, Schernthaner R, Chapiro J, Lee H, Sahu S, Nguyen S, Geschwind JF, Lin M. Radiologic-pathologic analysis of quantitative 3D tumour enhancement on contrast-enhanced MR imaging: a study of ROI placement. Eur Radiol 2016;26:103-13. [PMID: 25994198 DOI: 10.1007/s00330-015-3812-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
32 Schneider T, Chapiro J, Lin M, Geschwind JF, Kleinberg L, Rigamonti D, Jusué-Torres I, Marciscano AE, Yousem DM. 3D quantitative assessment of response to fractionated stereotactic radiotherapy and single-session stereotactic radiosurgery of vestibular schwannoma. Eur Radiol 2016;26:849-57. [PMID: 26139318 DOI: 10.1007/s00330-015-3895-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
33 Lewis H, Ghasabeh M, Khoshpouri P, Kamel I, Pawlik T. Functional hepatic imaging as a biomarker of primary and secondary tumor response to loco-regional therapies. Surgical Oncology 2017;26:411-22. [DOI: 10.1016/j.suronc.2017.08.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
34 Thüring J, Kuhl CK, Barabasch A, Hitpass L, Bode M, Bünting N, Bruners P, Krämer NA. Signal changes in T2-weighted MRI of liver metastases under bevacizumab-A practical imaging biomarker? PLoS One 2020;15:e0230553. [PMID: 32231380 DOI: 10.1371/journal.pone.0230553] [Reference Citation Analysis]
35 Tacher V, Lin M, Duran R, Yarmohammadi H, Lee H, Chapiro J, Chao M, Wang Z, Frangakis C, Sohn JH. Comparison of Existing Response Criteria in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using a 3D Quantitative Approach. Radiology. 2016;278:275-284. [PMID: 26131913 DOI: 10.1148/radiol.2015142951] [Cited by in Crossref: 51] [Cited by in F6Publishing: 55] [Article Influence: 7.3] [Reference Citation Analysis]
36 Amorim J, França M, Perez-girbes A, Torregrosa A, Martí-bonmatí L. Critical review of HCC imaging in the multidisciplinary setting: treatment allocation and evaluation of response. Abdom Radiol 2020;45:3119-28. [DOI: 10.1007/s00261-020-02470-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
37 Nezami N, VAN Breugel JMM, Konstantinidis M, Chapiro J, Savic LJ, Miszczuk MA, Rexha I, Lin M, Hong K, Georgiades C. Lipiodol Deposition and Washout in Primary and Metastatic Liver Tumors After Chemoembolization. In Vivo 2021;35:3261-70. [PMID: 34697157 DOI: 10.21873/invivo.12621] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Hinrichs JB, Shin H, Kaercher D, Hasdemir D, Murray T, Kaireit T, Lutat C, Vogel A, Meyer BC, Wacker FK, Rodt T. Parametric response mapping of contrast-enhanced biphasic CT for evaluating tumour viability of hepatocellular carcinoma after TACE. Eur Radiol 2016;26:3447-55. [DOI: 10.1007/s00330-015-4203-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
39 Ghani MA, Fereydooni A, Chen E, Letzen B, Laage-Gaupp F, Nezami N, Deng Y, Gan G, Thakur V, Lin M, Papademetris X, Schernthaner RE, Huber S, Chapiro J, Hong K, Georgiades C. Identifying enhancement-based staging markers on baseline MRI in patients with colorectal cancer liver metastases undergoing intra-arterial tumor therapy. Eur Radiol 2021. [PMID: 34061209 DOI: 10.1007/s00330-021-08058-7] [Reference Citation Analysis]
40 Pandey A, Pandey P, Aliyari Ghasabeh M, Najmi Varzaneh F, Shao N, Khoshpouri P, Zarghampour M, Fouladi DF, Liddell R, Kamel IR. Unresectable Intrahepatic Cholangiocarcinoma: Multiparametric MR Imaging to Predict Patient Survival. Radiology 2018;288:109-17. [DOI: 10.1148/radiol.2018171593] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
41 Sobhani F, Xu C, Murano E, Pan L, Rastegar N, Kamel IR. Hypo-Vascular Liver Metastases Treated with Transarterial chemoembolization: Assessment of Early Response by Volumetric Contrast-Enhanced and Diffusion-Weighted Magnetic Resonance Imaging. Transl Oncol 2016;9:287-94. [PMID: 27567951 DOI: 10.1016/j.tranon.2016.03.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
42 Xu C, Sobhani F, Murano E, Corona-Villalobos C, Pozzessere C, Rastegar N, Kamel IR. Liver Malignancies Treated With Intra-Arterial Therapy: Assessment of Early Response as Quantified by Volumetric Enhancement Using Gadoxetate Disodium. J Comput Assist Tomogr 2016;40:206-11. [PMID: 26720204 DOI: 10.1097/RCT.0000000000000348] [Reference Citation Analysis]
43 Chen BB, Hsu CY, Yu CW, Liang PC, Hsu C, Hsu CH, Cheng AL, Shih TT. Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma. Eur Radiol 2017;27:3069-79. [PMID: 27957638 DOI: 10.1007/s00330-016-4670-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
44 Gregory J, Dioguardi Burgio M, Corrias G, Vilgrain V, Ronot M. Evaluation of liver tumour response by imaging. JHEP Rep 2020;2:100100. [PMID: 32514496 DOI: 10.1016/j.jhepr.2020.100100] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
45 Reimer RP, Reimer P, Mahnken AH. Assessment of Therapy Response to Transarterial Radioembolization for Liver Metastases by Means of Post-treatment MRI-Based Texture Analysis. Cardiovasc Intervent Radiol 2018;41:1545-56. [PMID: 29881933 DOI: 10.1007/s00270-018-2004-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
46 Cai WL, Hong GB. Quantitative image analysis for evaluation of tumor response in clinical oncology. Chronic Dis Transl Med 2018;4:18-28. [PMID: 29756120 DOI: 10.1016/j.cdtm.2018.01.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
47 Koulakian H, Allaham W, Vilgrain V, Ronot M. Non-measurable infiltrative HCC: is post-contrast attenuation on CT a sign of tumor response? Eur Radiol 2019;29:4389-99. [PMID: 30413965 DOI: 10.1007/s00330-018-5805-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]